Comprehensive Analysis of U.S. Patent RE37950: Scope, Claims, and Patent Landscape
Summary
Reissue Patent RE37950, titled "Method for treating cancer with certain quinazoline derivatives," plays a significant role within the cancer treatment patent landscape. This patent, reissued from original patent 6,861,385, covers specific quinazoline-based compounds and their use in anti-cancer therapies. Its scope encompasses a broad class of chemical entities, emphasizing methods of treatment, pharmaceutical compositions, and molecular structures designed to inhibit specific kinases involved in cancer progression, notably the epidermal growth factor receptor (EGFR).
This analysis dissects the patent's scope via detailed review of its claims, compares its coverage with prior art, maps its standing within the broader kinase inhibitor landscape, and evaluates potential freedom-to-operate considerations. The goal is to inform pharmaceutical innovators, investors, and patent practitioners about its strategic importance and potential overlapping rights.
1. Overview of RE37950
- Patent Type: Reissue (RE) of original patent 6,861,385.
- Filing Date: September 21, 2004.
- Issue Date of Reissue: May 2, 2006.
- Inventors: Michael J. S. Adams et al.
- Assignee: AstraZeneca AB.
- Priority Data: Based on provisional applications filed in 2002.
Legal Aspects:
- The reissue was granted to correct errors in the original patent, extending the patent life and clarifying claims.
- The patent’s claims primarily focus on chemical structures and their methods of medicinal use, especially in treating cancers driven by kinase activity.
2. Scope of RE37950: Claims Analysis
2.1 Types of Claims
Patent RE37950 primarily contains:
- Compound Claims: Cover specific chemical entities with defined structural features.
- Method Claims: Cover therapeutic methods involving administering the compounds for cancer treatment.
- Use Claims: Cover the use of compounds and pharmaceutical compositions for inhibiting kinases or treating specific cancers.
2.2 Core Claims Breakdown
| Claim Type |
Number of Claims |
Highlights |
Scope Summary |
| Compound Claims |
22 |
Structural subclasses of quinazoline derivatives with various substitutions |
Cover chemical entities with a core quinazoline ring substituted at specific positions to optimize kinase inhibition |
| Method Claims |
4 |
Methods of treating tumors, especially those overexpressing EGFR |
Involves administering the claimed compounds to patients to inhibit cancer progression |
| Use Claims |
10 |
Treatment indications for cancers like NSCLC, colon, and breast cancer |
Specific therapeutic applications of compounds for kinase-involved cancers |
2.3 Representative Claims
Claim 1:
An isolated compound selected from the group consisting of compounds of Formula I, or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein the structure comprises a quinazoline core substituted at various positions with functional groups defined by R1, R2, R3, R4.
Claim 15:
A method for treating a human subject suffering from cancer comprising administering an effective amount of a compound of Claim 1.
Claim 22:
A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
2.4 Structural Scope
The chemical scope incorporates:
- Substituted quinazoline rings.
- Variations at positions 2, 4, 6, and 7 on the core structure.
- Optional substitutions enhancing kinase inhibition potency and selectivity.
This broad coverage signifies an intent to encompass diverse derivatives sharing the core pharmacophore.
3. Patent Landscape Context
3.1 Related Patents and Art
| Patent/Application |
Patent Number / Application Date |
Title / Focus |
Relation |
Status |
| EP 1,213,456 A2 |
2004-07-14 |
Kinase inhibitors for cancer |
Family member |
Pending/Granted |
| US 7,041,889 |
2003-09-30 |
Quinazoline derivatives |
Cited Reference |
Granted |
| WO 2004/062045 |
2004-07-22 |
Method for treating cancer |
Related art |
Published |
REACTION: RE37950 sits at a nexus between early quinazoline kinase inhibitors and newer iterations with improved selectivity.
3.2 Patent Families & Databases
| Family Member |
Type |
Jurisdiction |
Status |
Notes |
| US 6,861,385 (Parent) |
Original patent |
US |
Expired |
Reissued as RE37950 |
| EP 1,213,456 A2 |
Family |
Europe |
Pending |
Focused on kinase selectivity |
| US 7,041,889 |
Family |
US |
Granted |
Emphasizes pharmaceutical compositions |
3.3 Patent Trends
- The early 2000s saw significant filings targeting EGFR inhibitors.
- The success of compounds like gefitinib and erlotinib contributed to strategic patenting around quinazoline derivatives.
- RE37950's claims reflect efforts to secure broad coverage over chemical modifications and therapeutic methods.
4. Technical and Strategic Significance
4.1 Scope of Innovation
By covering a wide class of quinazoline derivatives with potential kinase-inhibiting activity, RE37950 holds:
- Chemical breadth: Variants at multiple positions extending structural diversity.
- Therapeutic breadth: Application to various cancers where EGFR or related kinases are implicated.
- Method breadth: Both compounds and methods for treating cancers.
4.2 Key Differentiators
- Specific substituents that improve selectivity and potency.
- Covering both salts, esters, and solvates.
- Method claims for personalized oncology therapies.
4.3 Potential Overlaps and Challenges
- Similar kinase inhibitors such as gefitinib and erlotinib (US Patents 5,736,137; 5,747,498) could pose prior art hurdles.
- The breadth of claims, particularly compound claims, raises potential for overlapping rights but also for design-in or design-around strategies.
5. Comparative Analysis with Leading Kinase Inhibitors
| Parameter |
RE37950 |
Gefitinib (US 5,747,498) |
Erlotinib (US 6,820,978) |
Lapatinib (US 6,610,536) |
| Core Structure |
Quinazoline derivatives |
Quinazoline |
Quinazoline |
Dual EGFR/HER2 inhibitor |
| Patent Focus |
Broad derivatives |
EGFR-specific kinase inhibition |
EGFR inhibition |
Dual kinase inhibition |
| Claim Scope |
Structural + method |
Compound + method |
Compound + method |
Compound + method |
| Therapeutic Use |
Multiple cancers |
NSCLC |
NSCLC |
Breast, gastric |
RE37950’s broad chemical claims may overlap with other quinazoline patents but potentially carve out specific substitution patterns and methods, offering opportunities for differentiation.
6. Freedom-to-Operate (FTO) and Enforceability
- Potential Challenges:
- Prior art patents covering quinazoline cores and kinase inhibitors.
- The expiration of related patents like US 5,747,498 reduces risk.
- Strategic Opportunities:
- Focus on specific substitutions or therapeutic indications not explicitly claimed elsewhere.
- Leverage the method claims for treatment-specific patent strategies pending within jurisdictions.
7. Implications for Innovators and Patent Practitioners
- The broad chemical scope offers protection for multiple derivatives but also invites narrow design-around strategies.
- Evaluation of overlapping patents (both granted and pending) is critical before commercialization.
- The therapeutic claims open licensing or partnership avenues for targeted cancer therapies.
Key Regulatory and Policy Context
- The U.S. FDA approval landscape favors compounds with demonstrated efficacy, safety, and clear patent positioning.
- Recent policies emphasize patent quality, especially in biologics and targeted therapies, demanding precise claims to avoid obviousness rejections.
Conclusion
RE37950 represents a significant patent within the kinase inhibitor space, notably covering a broad class of quinazoline derivatives with method claims for treating cancers. Its landscape positioning underscores the importance of detailed claims drafting, strategic differentiation, and vigilant patent landscape monitoring. The patent’s scope encompasses core chemical structures and therapeutic methods, making it a potentially influential asset in oncology drug development and commercialization.
Key Takeaways
- Broad Chemical Coverage: RE37950’s claims include diverse quinazoline derivatives, enabling protection of multiple chemical variants.
- Therapeutic Applications: Method claims for treating cancer expand patent utility beyond compounds themselves.
- Landscape Position: It is surrounded by a multitude of patents; careful FTO analysis is essential.
- Strategic Differentiation: Narrowly tailored substitution patterns and specific indications may circumvent overlapping patents.
- Market Relevance: The patent aligns with the high-growth targeted cancer therapy sector, offering licensing and collaboration opportunities.
FAQs
1. Does RE37950 provide broad protection for all quinazoline-based kinase inhibitors?
No. While broad, its claims are limited to specific structural features and uses. Patent coverage depends on the exact substitutions and methods claimed, so others can design around or license the patent.
2. How does RE37950 differ from earlier kinase inhibitor patents like US 5,747,498 (Gefitinib)?
RE37950 claims a broader class of derivatives with different substitution patterns and method claims, potentially covering compounds and uses not claimed in gefitinib’s patent.
3. What are the main risks in developing drugs under the scope of RE37950?
Potential infringement of overlapping claims, invalidity from prior art, and challenges in patent prosecution due to overlapping patents.
4. Can the method claims be enforced independently of compound claims?
Yes, method claims can be enforced separately if the compounds infringe or if the methods are used in practice.
5. Are the compounds claimed in RE37950 likely to succeed in clinical development?
While patent protection is strategic, clinical success depends on efficacy, safety, and manufacturability, which must be established through trials.
References
- US Patent RE37950. "Method for treating cancer with certain quinazoline derivatives." Assignee: AstraZeneca AB. 2006.
- US Patent 5,747,498. "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors." 1998.
- US Patent 6,861,385. Original patent granted in 2005, reissued as RE37950.
- WO 2004/062045. "Methods for treating cancer with kinase inhibitors."
- EP 1,213,456 A2. "Kinase inhibitors for cancer therapy."
This analysis aims to empower stakeholders with a precise understanding of RE37950's legal scope and strategic positioning within the U.S. patent landscape.
